| pMSCV-LTR-dCas9-VP64-BFP | dCas9-VP64-BFP fusion (Homo sapiens), Puromycin resistance | LTR, PGK | Puromycin |
Qi
| CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes.
Cell. 2013 Jul 9. pii: S0092-8674(13)00826-X. doi: 10.1016/j.cell.2013.06.044.
|
Human expression vector containing MSCV LTR promoter, dCas9 that is fused to 2x NLS, VP64 and tagBFP
MSCV-puro
|
| pMSCV-LTR-dCas9-p65AD-BFP | dCas9-p65AD-BFP fusion (Homo sapiens), Puromycin resistance | LTR, PGK | Puromycin |
Qi
| CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes.
Cell. 2013 Jul 9. pii: S0092-8674(13)00826-X. doi: 10.1016/j.cell.2013.06.044.
|
Human expression vector containing MSCV LTR promoter, dCas9 that is fused to 2x NLS, p65 activation domain and tagBFP
MSCV-puro
|
| pcDNA-dCas9-VP64 | dCas9-VP64 (Other) | CMV | |
Gersbach
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors.
Nat Methods. 2013 Jul 25. doi: 10.1038/nmeth.2600.
|
Expresses inactivated S. pyogenes dCas9 (D10A, H840A) fused to VP64 transactivator domain in mammalian cells
pcDNA3.1
|
| Cas9m2-VP64 | Cas9m2-VP64 (Other) | | |
Church
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol. 2013 Aug 1. doi: 10.1038/nbt.2675.
|
Cas9m2 Activator
pcDNA3.3_TOPO
|
| Cas9m3-VP64 | Cas9m3-VP64 (Other) | | |
Church
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol. 2013 Aug 1. doi: 10.1038/nbt.2675.
|
Cas9m3 Activator
pcDNA3.3_TOPO
|
| Cas9m4-VP64 | Cas9m4-VP64 (Other) | | |
Church
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol. 2013 Aug 1. doi: 10.1038/nbt.2675.
|
Cas9m4 Activator
pcDNA3.3_TOPO
|
| pSL690 | dCas9-VP64 (Synthetic) | CMV | |
Joung
| CRISPR RNA-guided activation of endogenous human genes.
Nat Methods. 2013 Jul 25. doi: 10.1038/nmeth.2598.
|
Expresses dCas9-VP64 fusion
unknown
|
| pMLM3705 | codon optimized dCas9-VP64 (Synthetic) | CMV | |
Joung
| CRISPR RNA-guided activation of endogenous human genes.
Nat Methods. 2013 Jul 25. doi: 10.1038/nmeth.2598.
|
Expresses mammalian cell codon-optimized dCas9-VP64
pJDS246
|
| pAC1-pCR8-dCas9VP48 | dCas9(D10A;H840A) fusion with VP48 activation domain (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP48 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC147-pCR8-dCas9VP64 | dCas9(D10A;H840A) fusion with VP64 activation domain (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP64 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC148-pCR8-dCas9VP96 | dCas9(D10A;H840A) fusion with VP96 activation domain (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP96 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC149-pCR8-dCas9VP160 | dCas9(D10A;H840A) fusion with VP160 activation domain (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC91-pmax-dCas9VP64 | dCas9(D10A;H840A) fusion with VP64 activation domain (Homo sapiens) | CAGGS | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP64 on pmax expression vector
pmax-DEST (Addgene: 48222)
|
| pAC92-pmax-dCas9VP96 | dCas9(D10A;H840A) fusion with VP96 activation domain (Homo sapiens) | CAGGS | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP96 on pmax expression vector
pmax-DEST (Addgene: 48222)
|
| pAC93-pmax-dCas9VP160 | dCas9(D10A;H840A) fusion with VP160 activation domain (Homo sapiens) | CAGGS | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160 on pmax expression vector
pmax-DEST (Addgene: 48222)
|
| pAC94-pmax-dCas9VP160-2A-puro | dCas9(D10A;H840A) fusion with VP160 activation domain followed by 2A-puro (Homo sapiens) | CAGGS | Puromycin |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160-2A-puro (puro-selectable) on pmax expression vecor. Note: This is being tested.
pmax-DEST (Addgene: 48222)
|
| pAC95-pmax-dCas9VP160-2A-neo | dCas9(D10A;H840A) fusion with VP160 activation domain followed by 2A-neo (Homo sapiens) | CAGGS | Neomycin (select with G418) |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160-2A-neo (neo/G418-selectable) on pmax expression vector. Note: This is being tested.
pmax-DEST (Addgene: 48222)
|
| pAC2-dual-dCas9VP48-sgExpression | dCas9VP48 (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP48 and sgRNA from separate promoters
pX335 (Addgene #42335)
|
| pAC5-dual-dCas9VP48-sgTetO | dCas9VP48 and sgTetO (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP48 and sgTetO from separate promoters
pAC2-dual-dCas9VP48-sgExpression (Addgene #48236)
|
| pAC152-dual-dCas9VP64-sgExpression | dCas9 (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP64 and sgRNA from separate promoters
pX335 (Addgene #42335)
Tags
/ Fusion Proteins- HA-Tag (N terminal on insert)
- VP64 (C terminal on insert)
|
| pAC153-dual-dCas9VP96-sgExpression | dCas9 (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP96 and sgRNA from separate promoters
pX335 (Addgene #42335)
Tags
/ Fusion Proteins- HA-Tag (N terminal on insert)
- VP96 (C terminal on insert)
|
| pAC154-dual-dCas9VP160-sgExpression | dCas9 (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP160 and sgRNA from separate promoters
pX335 (Addgene #42335)
Tags
/ Fusion Proteins- HA-Tag (N terminal on insert)
- VP160 (C terminal on insert)
|
| M-SPn-VP64 | Cas9-VP64, nuclease-null (Other) | CMV | Neomycin (select with G418) |
Church
| Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.
Nat Methods. 2013 Sep 29. doi: 10.1038/nmeth.2681.
|
Mammalian SP-VP64 nuclease-null Cas9 activator expression, human optimized
pcDNA3.3 TOPO
|
| M-ST1n-VP64 | Cas9-VP64, nuclease-null (Other) | CMV | Neomycin (select with G418) |
Church
| Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.
Nat Methods. 2013 Sep 29. doi: 10.1038/nmeth.2681.
|
Mammalian ST1-VP64 nuclease-null Cas9 activator expression, human optimized
pcDNA3.3 TOPO
|
| M-NMn-VP64 | Cas9-VP64, nuclease-null (Other) | CMV | Neomycin (select with G418) |
Church
| Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.
Nat Methods. 2013 Sep 29. doi: 10.1038/nmeth.2681.
|
Mammalian NM-VP64 nuclease-null Cas9 activator expression, human optimized
pcDNA3.3 TOPO
|
| pCMV_dCas9_VP64 | dCas9_VP64 (human-codon-optimized) (Homo sapiens) | CMV | |
Lu
| Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas.
ACS Synth Biol. 2013 Sep 11.
|
encodes human-optimized dCas9_VP64 synthetic transcription factor
phi-Yellow-Dest
|
| pHAGE TRE dCas9-VP64 | dCas9 (Other) | TRE | Neomycin (select with G418) |
Wolfe
| Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells.
Development. 2014 Jan;141(1):219-23. doi: 10.1242/dev.103341.
|
Tet-regulatable dCas9-VP64 2nd generation lentiviral expression vector
pHAGE
|
| pHAGE EF1α dCas9-VP64 | dCas9 (Other) | EF1alpha | Puromycin |
Wolfe
| Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells.
Development. 2014 Jan;141(1):219-23. doi: 10.1242/dev.103341.
|
Constitutive dCas9-VP64 lentiviral expression vector
pHAGE
|
| pLV hUbC-dCas9 VP64-T2A-GFP | humanized dead Cas9 VP64 T2A GFP (Other) | hUbC | |
Gersbach
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
Nucleic Acids Res. 2014 Aug 13. pii: gku749.
|
Co-expresses human optimized S. pyogenes dCas9-VP64 and GFP
FUGW
|
| CMVp-dCas9-3xNLS-VP64 (Construct 1) | dCas9 (Homo sapiens) | CMV/hUBC | |
Lu
| Multiplexed and Programmable Regulation of Gene Networks with an Integrated RNA and CRISPR/Cas Toolkit in Human Cells.
Mol Cell. 2014 May 14. pii: S1097-2765(14)00355-4. doi: 10.1016/j.molcel.2014.04.022.
|
Expresses taCas9 in Mammalian cells for transactivating endogenous and synthetic promoters. The backbone is a lentiviral vector.
pFUGw (Addgene id: 25870)
|
| pLV hUbC-VP64 dCas9 VP64-T2A-GFP | humanized VP64 dead Cas9 VP64 T2A GFP (Other) | | |
Gersbach
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
Nucleic Acids Res. 2014 Aug 13. pii: gku749.
|
Co-expresses human optimized S. pyogenes dCas9 fused to two copies of VP64 and GFP
FUGW
|
| pcDNA3.1-CibN-dCas9 | CibN-dCas9 (Arabidopsis thaliana) | CMV | Neomycin (select with G418) |
Gersbach
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Nat Chem Biol. 2015 Feb 9. doi: 10.1038/nchembio.1753.
|
Expresses CibN-dCas9 in mammalian cells
pcDNA3.1
|
| pcDNA3.1-dCas9-CibN | dCas9-CibN (Arabidopsis thaliana) | CMV | Neomycin (select with G418) |
Gersbach
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Nat Chem Biol. 2015 Feb 9. doi: 10.1038/nchembio.1753.
|
Expresses dCas9-CibN in mammalian cells
pcDNA3.1
|
| pcDNA3.1-CibN-dCas9-CibN | dCas9-CibN (Arabidopsis thaliana) | CMV | Neomycin (select with G418) |
Gersbach
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Nat Chem Biol. 2015 Feb 9. doi: 10.1038/nchembio.1753.
|
Expresses CibN-dCas9-CibN in mammalian cells
pcDNA3.1
|
| pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP | Cas9 dead | | |
Vale
| A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging.
Cell. 2014 Oct 8. pii: S0092-8674(14)01227-6. doi: 10.1016/j.cell.2014.09.039.
|
Expressed a nuclease dead Cas9 tagged with 10 copies of the GCN4 peptide v4 and BFP. This plasmid is part of the SunTag system for gene activation
pHR
|
| pHRdSV40-scFv-GCN4-sfGFP-VP64-GB1-NLS | scFv-GCN4 | | |
Vale
| A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging.
Cell. 2014 Oct 8. pii: S0092-8674(14)01227-6. doi: 10.1016/j.cell.2014.09.039.
|
The plasmid encodes a antibody that binds to the GCN4 peptide from the SunTag system, and is fused to a transcriptional activation domain VP64
pHR
|
| pHRdSV40-NLS-dCas9-24xGCN4_v4-NLS-P2A-BFP-dWPRE | dCas9 | dSV40 Promoter | |
Vale
| A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging.
Cell. 2014 Oct 8. pii: S0092-8674(14)01227-6. doi: 10.1016/j.cell.2014.09.039.
|
dCas9 fused to 24 copies of the GCN4 peptide v4, which is part of the SunTag system
pHR
|
| dCAS9-VP64_GFP | dCAS9(D10A,H840A)-VP64_2A_GFP (Synthetic) | EF1A | GFP |
Zhang
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
Nature. 2014 Dec 10. doi: 10.1038/nature14136.
|
Expresses dCAS9-VP64 activator with 2A GFP
lenti(AMP)
|
| lenti dCAS-VP64_Blast | dCAS9(D10A, N863A)-VP64_2A_Blast (Synthetic) | EF1A | Blasticidin |
Zhang
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
Nature. 2014 Dec 10. doi: 10.1038/nature14136.
|
3rd generation lenti vector encoding dCAS9-VP64 with 2A Blast resistance marker (EF1a-NLS-dCas9(N863)-VP64-2A-Blast-WPRE)
plenti
|
| TetO-FUW-VdC9BV | VP64dCas9BFPVP64 (Synthetic) | | |
Leong
| A CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification.
Stem Cell Reports. 2014 Dec 9;3(6):940-7. doi: 10.1016/j.stemcr.2014.09.013. Epub 2014 Oct 23.
|
Expresses RNA-Guided, Nuclease-Inactive VP64:dCas9-BFP:VP64—VdC9BV—Fusion Protein to Enable Transactivation of Endogenous Genes
TetO-FUW
|
| pJZC32 | sgRNA, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA (no RNA aptamer addition) with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC25 | sgRNA + 1x MS2 binding module, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1x MS2 with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC33 | sgRNA + 2x MS2 binding module, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2x MS2 with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC34 | sgRNA + 2x MS2(wt+f6) binding module, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2x MS2(wt+f6) with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC41 | sgRNA, PCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA (no RNA aptamer addition) with PCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC39 | sgRNA + 1x PP7, mCherry | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1x PP7 with mCherry for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC101 | sgRNA, COM-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA (no RNA aptamer addition) with COM-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC48 | sgRNA + 1x COM binding module, COM-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1x COM with COM-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC116 | sgRNA + 2x MS2 (wt+f6) binding module, MCP-VP64 | U6, CMV | Marked by BFP |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2x MS2(wt+f6) with MCP-VP64 effector for mammalian cells, marked by BFP
MP177_U6 (derived from pSico)
|
| PX855 | SpCas9 (aa 2-535) | CBh | |
Zhang
| A split-Cas9 architecture for inducible genome editing and transcription modulation.
Nat Biotechnol. 2015 Feb 2. doi: 10.1038/nbt.3149.
|
N-term SpCas9 piece of inducible transcriptional activator (dCas9(N)-FRB-2xNES)
PX330
|
| PX856 | SpCas9 (aa536-1368) | CBh | |
Zhang
| A split-Cas9 architecture for inducible genome editing and transcription modulation.
Nat Biotechnol. 2015 Feb 2. doi: 10.1038/nbt.3149.
|
C-term SpCas9 piece of inducible transcriptional activator (dCas9(C)-FKBP-2xNLS-VP64)
PX330
|
| px330-CIB1-dCas9 | | U6 and CMV | |
Kong
| Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer
Theranostics
|
Mammalian gRNA expression vector also expressing CIB1-dCas9
px330
|
| SP-dCas9-VPR | SP-dCas9-VPR (Homo sapiens) | CMV | Neomycin (select with G418) |
Church
| Highly efficient Cas9-mediated transcriptional programming.
Nat Methods. 2015 Mar 2. doi: 10.1038/nmeth.3312.
|
SP-dCas9 with VP64-p65-Rta (VPR) fused to it's C-terminus; mammalian vector
pcDNA3.3 TOPO
|
| M_ST1n_VPR | ST1-dCas9-VPR (Homo sapiens) | CMV | Neomycin (select with G418) |
Church
| Highly efficient Cas9-mediated transcriptional programming.
Nat Methods. 2015 Mar 2. doi: 10.1038/nmeth.3312.
|
ST1-dCas9 with VP64-p65-Rta (VPR) fused to it's C-terminus; mammalian vector
pcDNA3.3 TOPO
|
| PB-TRE-dCas9-VPR | dCas9-VPR (Homo sapiens) | TRE | Hygromycin |
Church
| Highly efficient Cas9-mediated transcriptional programming.
Nat Methods. 2015 Mar 2. doi: 10.1038/nmeth.3312.
|
SP-dCas9-VPR with doxycycline-inducible expression
PB-TRE
|
| NLS-dCas9-trCIB1 | dCas9-trCIB1 fusion (Synthetic) | CMV | Neomycin (select with G418) |
Sato
| CRISPR-Cas9-based Photoactivatable Transcription System.
Chem Biol. 2015 Feb 19;22(2):169-74. doi: 10.1016/j.chembiol.2014.12.011. Epub 2015 Jan 22.
|
Photoactivatable transcription system. Expression of genomic anchor probe, containing
dCas9 and CIB1
pcDNA3.1/V5-His A
|
| pJZC42 | sgRNA + 1XPP7, PCP-VP64 IRES mCherry | U6, CMV | mCherry fluorescence |
Lim
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1XPP7 with PCP-VP64 effector for mammalian cells, marked by mCherry
pSico
|
| pJZC43 | sgRNA + 2XPP7, PCP-VP64 IRES mCherry | U6, CMV | mCherry fluorescence |
Lim
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2XPP7 with PCP-VP64 effector for mammalian cells, marked by mCherry
pSico
|
| pLV hU6-gRNA(anti-sense) hUbC-VP64-dCas9-VP64-T2A-GFP | hU6-gRNA expression cassette (Synthetic), S.Pyogenes VP64-dCas9-VP64 (Other) | hU6, hUbC | |
Gersbach
|
Multiplex CRISPR/Cas9 Genome Engineering for Directing Myogenic Cellular Differentiation in Primary Human Cells
(unpublished)
|
expresses a single gRNA and VP64-dCas9-VP64
FUGW
|
| pLV hUbC- VP64-dCas9-VP64-T2A- GFP(No LoxP sites) | S.Pyogenes VP64-dCas9-VP64 (Other) | hUbC | |
Gersbach
|
Multiplex CRISPR/Cas9 Genome Engineering for Directing Myogenic Cellular Differentiation in Primary Human Cells
(unpublished)
|
expresses VP64-dCas9-VP64, same plasmid as Addgene 59791 but with LoxP sites removed
FUGW
|
| pEF_dCas9-VP64 | dCas9 (Other) | human EF1[alpha] | |
Rinn
| Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display.
Nat Methods. 2015 Jul;12(7):664-70. doi: 10.1038/nmeth.3433. Epub 2015 Jun 1.
|
Transient expression of Sp-dCas9 fused to the VP64 transcription activator, in mammalian cells, under an EF1-alpha promoter.
pNEB193
Tags
/ Fusion Proteins- 3xFLAG (C terminal on insert)
- VP64 (C terminal on insert)
|
| AAV_NLS-dSaCas9-NLS-VPR | dSaCas9-VPR (Synthetic) | CMV | |
Church
| Cas9 gRNA engineering for genome editing, activation and repression.
Nat Methods. 2015 Sep 7. doi: 10.1038/nmeth.3580.
|
AAV vector containing nuclease null SaCas9 fused to VPR
pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA Plasmid #61592
|
| CAG-DDdCas9VP192-T2A-EGFP-ires-puro | DD-dCas9VP192-T2A-EGFP (Other) | CAG | Puromycin |
Otonkoski
| Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.
|
DHFR destabilised domain (DD) fused to dCas9VP192 (S.pyogenes) on CAG expression vector. DDdCas9VP192 protein is stabilised by Trimethoprim.
PyCAG
|
| pCXLE-dCas9VP192-T2A-EGFP-shP53 | dCas9-dCas9VP192-GFP-shp53 (Other) | CAG | |
Otonkoski
| Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.
|
Episomal plasmid encoding dCas9VP192 and p53 shRNA
pCXLE
|
| pCXLE-dCas9VP192-T2A-EGFP | dCas9-dCas9VP192-EGFP (Other) | CAG | |
Otonkoski
| Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.
|
Episomal plasmid encoding dCas9VP192
pCXLE
|
| pHRm-NLS-dCas9-GFP11x7-NLS | NLS-dCas9-GFP11x7-NLS (Synthetic) | | |
Huang
| Versatile protein tagging in cells with split fluorescent protein.
Nat Commun. 2016 Mar 18;7:11046. doi: 10.1038/ncomms11046.
|
Expresses NLS-dCas9-GFP11x7-NLS in mammalian cells
pHRdSV40-NLS-dCas9-24xGCN4_v4-NLS-P2A-BFP-dWPRE (addgene #60910)
|
| pAC164-pmax-dCas9Master-VP64 | dCas9-VP64 (Synthetic) | CAGGS + chim intron | |
Cheng
| Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.
Cell Res. 2016 Feb;26(2):254-7. doi: 10.1038/cr.2016.3. Epub 2016 Jan 15.
|
dCas9-3xGGGGS-VP64 in pmax expression vector
pAC90-pmax-DEST
|
| pAC1364-pmax-dCas9Master_mCBPHAT | dCas9-mCBPHAT (Synthetic) | CAGGS + chim intron | |
Cheng
| Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.
Cell Res. 2016 Feb;26(2):254-7. doi: 10.1038/cr.2016.3. Epub 2016 Jan 15.
|
dCas9Master_mCBPHAT in pmax expression vector
pAC90-pmax-DEST
|
| pAC1410-pmax-dCas9Master_p65HSF1 | dCas9-p65HSF1 (Synthetic) | CAGGS + chim intron | |
Cheng
| Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.
Cell Res. 2016 Feb;26(2):254-7. doi: 10.1038/cr.2016.3. Epub 2016 Jan 15.
|
dCas9Master_p65HSF1 in pmax expression vector
pAC90-pmax-DEST
|
| lentiSAMv2 | | U6 and EF1A | Blasticidin |
Zhang
| Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.
Nat Protoc. 2017 Apr;12(4):828-863. doi: 10.1038/nprot.2017.016. Epub 2017 Mar 23.
|
lenti sgRNA cloning backbone with MS2 loops at tetraloop and stemloop 2, dCas9-VP64, and blast resistance marker. Contains BsmBI sites for insertion of spacer sequences.
plenti
|
| AAVS1-idCas9-vpr | dCas9-VPR (Other) | TRE-tight | Puromycin |
Na
| An inducible CRISPR-ON system for controllable gene activation in human pluripotent stem cells.
Protein Cell. 2017 Jan 23. doi: 10.1007/s13238-016-0360-8.
|
inducible CRISPR-ON system for controllable gene activation; this plasmid is used to insert dCas9-VPR casette in one allele of AAVS1 locus
AAVS1 homologous recombineering donor plasmid
|
| lentiSAM v2 (Puro) | | U6 (sgRNA) and EF1a (dCas9-VP64) | Puromycin |
Karpf
|
Lenti CRISPR Activate
(unpublished)
|
Modified version of lentiSAM v2, a lenti sgRNA cloning backbone with MS2 loops at tetraloop/stemloop 2, dCas9-VP64, and puro resistance marker. Contains BsmBI sites for insertion of spacer sequences.
lentiSAM v2
|
| pXPR_120 | dCas9 (Other) | EF1a | Blasticidin |
Root
| Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens.
Nat Biotechnol. 2018 Feb;36(2):179-189. doi: 10.1038/nbt.4048. Epub 2017 Dec 18.
|
for CRISPRa, lentiviral expression of dCas9-VPR 2A BlastR
pXPR
Tag
/ Fusion Protein- VPR (C terminal on insert)
|
| lenti-EF1a-dCas9-VP64-Puro | dCas9-VP64-T2A-Puro (Synthetic) | EF-1a | Puromycin, Zeocin |
Brennand
| Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.
Stem Cell Reports. 2017 Aug 8;9(2):615-628. doi: 10.1016/j.stemcr.2017.06.012. Epub 2017 Jul 27.
|
3rd generation lenti vector encoding dCas9-VP64 with 2A puromycin resistance marker (EF1a-dCas9-VP64-T2A-Puro-WPRE)
pLenti
|
| lenti-EF1a-dCas9-VPR-Puro | (Sp)dCas9-VPR-P2A-Puro (Homo sapiens) | EF-1a | Puromycin, Zeocin |
Brennand
| Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.
Stem Cell Reports. 2017 Aug 8;9(2):615-628. doi: 10.1016/j.stemcr.2017.06.012. Epub 2017 Jul 27.
|
3rd generation lenti vector encoding dCas9 (S. pyogenes) fused with VP64-p65-Rta (VPR) and 2A puromycin resistance marker; EF1a-dCas9-VPR-P2A-Puro-WPRE)
pLenti
|
| pAAV-dSa-VPR | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses tripartite VP64-p65-RTA activator fused to C term. of dead Sa Cas9
pAAV (pUC f1)
Tag
/ Fusion Protein- VP64-p65-RTA activator (C terminal on insert)
|
| dSp-p65 Full (1-261) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to p65 activation domain
pBR322
Tag
/ Fusion Protein- p65 activation domain (C terminal on insert)
|
| dSp-p65 (150-261) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (150-261) (C terminal on insert)
|
| dSp-p65 (100-261) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (100-261) (C terminal on insert)
|
| dSp-p65 (200-261) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (200-261) (C terminal on insert)
|
| dSp-p65 (1-200) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (1-200) (C terminal on insert)
|
| dSp-p65 (1-150) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (1-150) (C terminal on insert)
|
| dSp-p65 (1-100) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (1-100) (C terminal on insert)
|
| dSp-p65 (50-150) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated p65 activation domain
pBR322
Tag
/ Fusion Protein- truncated p65 activation domain (50-150) (C terminal on insert)
|
| dSp-Rta Full (1-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain (1-190) (C terminal on insert)
|
| dSp-Rta 75-190 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain (75-190) (C terminal on insert)
|
| dSp-Rta 125-190 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain ( 125-190) (C terminal on insert)
|
| dSp-Rta 50-175 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain (51-175) (C terminal on insert)
|
| dSp-Rta 75-175 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain (75-175) (C terminal on insert)
|
| dSp-Rta 100-175 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain (101-175) (C terminal on insert)
|
| dSp-Rta 125-175 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to truncated RTA activation domain
pBR322
Tag
/ Fusion Protein- truncated RTA activation domain (125-175) (C terminal on insert)
|
| dSp-VP64-RTA(75-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to combination of truncated activation domains
pBR322
Tag
/ Fusion Protein- VP64-RTA(75-190) (C terminal on insert)
|
| dSp-VP64-p65-RTA(75-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to combination of truncated activation domains
pBR322
Tag
/ Fusion Protein- VP64-p65-RTA(75-190) (C terminal on insert)
|
| dSp-VP64-p65(100-261)-RTA(75-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to combination of truncated activation domains
pBR322
Tag
/ Fusion Protein- VP64-p65(101-261)-RTA(75-190) (C terminal on insert)
|
| dSp-VP64-p65(100-261)-RTA(125-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to combination of truncated activation domains
pBR322
Tag
/ Fusion Protein- VP64-p65(101-261)-RTA(125-190) (C terminal on insert)
|
| dSp-VP64-p65(150-261)-RTA(125-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused to combination of truncated activation domains
pBR322
Tag
/ Fusion Protein- VP64-P65(151-261)-RTA(125-190) (C terminal on insert)
|
| dSp-VP64-RTA | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSp Cas9 fused at C term. To VP64 and RTA activation domains
pBR322
Tag
/ Fusion Protein- VP64-RTA (C terminal on insert)
|
| pAAV-dSa-VP64-p65(100-261)-RTA(125-190) | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to optimized combination of truncated activation domains
pAAV (pUC f1)
Tag
/ Fusion Protein- VP64-p65(101-261)-RTA(125-190) (C terminal on insert)
|
| pAAV-dSa-VP64 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to gold standard VP64 activator
pAAV (pUC f1)
Tag
/ Fusion Protein- VP64 (C terminal on insert)
|
| pAAV-SCP1-dSa-VPR mini. | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to optimized combination of truncated activation domains from EFS promoter
pAAV (pUC f1)
Tag
/ Fusion Protein- VPR mini (C terminal on insert)
|
| pAAV-EFS-dSa-VPR mini. | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to optimized combination of truncated activation domains from SCP1 promoter
pAAV (pUC f1)
Tag
/ Fusion Protein- VPR mini (C terminal on insert)
|
| pAAV-CMV-dSa-VPR mini.-1X snRP1 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to optimized combination of truncated activation domains with 17 nt snRP1 poly adenylation signal
pAAV (pUC f1)
Tag
/ Fusion Protein- VPR mini (C terminal on insert)
|
| pAAV-CMV-dSa-VPR mini.-2X snRP1 | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to optimized combination of truncated activation domains with 34 nt dual snRP1 poly adenylation signal
pAAV (pUC f1)
Tag
/ Fusion Protein- VPR mini (C terminal on insert)
|
| pAAV-CMV-dSa-VPR mini.-syn pA | dCas9 (Synthetic) | | |
Church
|
Church Lab CRISPR plasmids 2017
(unpublished)
|
Expresses dSa Cas9 fused to optimized combination of truncated activation domains with syn pA (poly adenylation) signal
pAAV (pUC f1)
Tag
/ Fusion Protein- VPR mini (C terminal on insert)
|
| PB-UniSAM | UniSAM-mCherry + U6-gRNA2.0 | EF1a | mCherry |
Forrester
| An all-in-one UniSam vector system for efficient gene activation
Scientific Reports
|
Encodes for Cas9-VP64, MS2-p65-HSF1, mCherry and for the gRNA 2.0
Piggy Bac
|
| pTMt_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | TMt-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to transmembrane tether
pX856
|
| pVEGFR1_TEV(C)_TCS(Q'G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | VEGFR1-dCas9(C) | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to VEGFR1
pTMt_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | BDKRB2-dCas9(N) | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to BDKRB2
pTMt_TCS(Q’G)_NLSHA- dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)_T2A_DHFR-PCP-VP64 | BDKRB2-dCas9(C)_DHFR-PCP-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C) with DHFR-PP7-VP64 fused to BDKRB2
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pAVPR2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | AVPR2-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to AVPR2
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pCXCR4_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | CXCR4-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to CXCR4
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pLPAR1_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | LPAR1-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to LPAR1
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| IGI-P0492 pHR-dCas9-NLS-VPR-mCherry | dCas9-VPR-mCherry (Homo sapiens) | CAG | mCherry |
Corn
|
Corn Lab Cas9 plasmids
(unpublished)
|
Lentiviral expression of dCas9-VPR-mCherry fusion protein for CRISPRa.
pHR
Tag
/ Fusion Protein- NLS-VPR-mCherry (C terminal on insert)
|
| PB-SAM | MS2-P65-HSF1_T2A_Hygro (Homo sapiens), dCAS9(D10A, N863A)-VP64_T2A_Blast (Synthetic) | EF1A, CAG | Hygromycin, Blasticidin |
Liu
| One-Step piggyBac Transposon-Based CRISPR/Cas9 Activation of Multiple Genes.
Mol Ther Nucleic Acids. 2017 Sep 15;8:64-76. doi: 10.1016/j.omtn.2017.06.007. Epub 2017 Jun 15.
|
Piggybac transposon vector encoding dCAS9-VP64 and MS2-P65-HSF1 activator helper complex.
piggybac
|
| PB-SAM-Dest | | N/A | Hygromycin, Blasticidin |
Liu
| One-Step piggyBac Transposon-Based CRISPR/Cas9 Activation of Multiple Genes.
Mol Ther Nucleic Acids. 2017 Sep 15;8:64-76. doi: 10.1016/j.omtn.2017.06.007. Epub 2017 Jun 15.
|
Piggybac transposon DEST vector encoding dCAS9-VP64 and MS2-P65-HSF1 activator helper complex. It is used for insertion of multiple U6-sgRNA expression cassettes.
PB-SAM
|
| PB-CAG-DDdCas9VP192-T2A-GFP-IRES-Neo | DDdCas9VP192-T2A-GFP-IRES-Neo (Other) | CAG | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with constitutive CAG promoter expression of TMP inducible DDdCas9VP192 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-CAG
|
| PB-CAG-DDdCas9VPH-T2A-GFP-IRES-Neo | DDdCas9VP192-p65-HSF1-T2A-GFP-IRES-Neo (Other) | CAG | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with constitutive CAG promoter expression of TMP inducible DDdCas9VP192-p65-HSF1 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-CAG
|
| PB-CAG-DDdCas9VPP300-T2A-GFP-IRES-Neo | DDdCas9VP192-P300-T2A-GFP-IRES-Neo (Other) | CAG | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with constitutive CAG promoter expression of TMP inducible DDdCas9VP192-P300core activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-CAG
|
| PB-CAG-DDdCas9VPPH-T2A-GFP-IRES-Neo | DDdCas9VP192-p65-HSF1-P300-T2A-GFP-IRES-Neo (Other) | CAG | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with constitutive CAG promoter expression of TMP inducible DDdCas9VP192-P300core-p65-HSF1 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-CAG
|
| PB-tight-DDdCas9VP192-T2A-GFP-IRES-Neo | DDdCas9VP192-T2A-GFP-IRES-Neo (Other) | TRE-tight | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with doxycyline inducible TRE-tight promoter expression of TMP inducible DDdCas9VP192 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-tight
|
| PB-tight-DDdCas9VPH-T2A-GFP-IRES-Neo | DDdCas9VP192-p65-HSF1-T2A-GFP-IRES-Neo (Other) | TRE-tight | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac construct with doxycyline inducible TRE-tight promoter expression of TMP inducible DDdCas9VP192-p65-HSF1 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-tight
|
| PB-tight-DDdCas9VPP300-T2A-GFP-IRES-Neo | DDdCas9VP192-P300-T2A-GFP-IRES-Neo (Other) | TRE-tight | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac construct with doxycyline inducible TRE-tight promoter expression of TMP inducible DDdCas9VP192-P300core activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-tight
|
| PB-tight-DDdCas9VPPH-T2A-GFP-IRES-Neo | DDdCas9VP192-p65-HSF1-P300-T2A-GFP-IRES-Neo (Other) | TRE-tight | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac construct with doxycyline inducible TRE-tight promoter expression of TMP inducible DDdCas9VP192-P300core-p65-HSF1 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-tight
|
| pCXLE-dCas9VPH-T2A-GFP-shP53 | dCas9VPH-T2A-GFP-shP53 (Other) | CAG | |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
EBNA episome plasmid for CAG promoter constitutive expression of dCas9-VP192-p65-HSF1 followed by T2A-GFP as a reporter. Includes p53 shRNA expression cassette.
pCXLE
|
| pCXLE-dCas9VPP300-T2A-GFP-shP53 | dCas9VPP300-T2A-GFP-shP53 (Other) | CAG | |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
EBNA episome plasmid for CAG promoter constitutive expression of dCas9-VP192-P300core followed by T2A-GFP as a reporter. Includes p53 shRNA expression cassette.
pCXLE
|
| pCXLE-dCas9VPPH-T2A-GFP-shP53 | dCas9VPPH-T2A-GFP-shP53 (Other) | CAG | |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
EBNA episome plasmid for CAG promoter constitutive expression of dCas9-VP192-P300core-p65-HSF1 followed by T2A-GFP as a reporter. Includes p53 shRNA expression cassette.
pCXLE
|
| PB-tight-DDdCas9GFP-IRES-Neo | DDdCas9GFP-IRES-Neo (Other) | TRE-tight | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac construct with doxycyline inducible TRE-tight promoter expression of dCas9-GFP followed by IRES-Neomycin selection cassette.
PB-tight
|
| pAW90.dCas9-YY1 | dCas9-YY1 | | Blasticidin |
Young
| YY1 Is a Structural Regulator of Enhancer-Promoter Loops.
Cell. 2017 Dec 14;171(7):1573-1588.e28. doi: 10.1016/j.cell.2017.11.008. Epub 2017 Dec 7.
|
Expresses dCas9-YY1
dcas9-vp64
|
| p-dCas9-VP64-Hygro | VP64 (Synthetic) | CMV promoter | Hygromycin |
Beck
|
Beck lab Cas9 plasmids
(unpublished)
|
transient expression of dCas9-VP64 fusion protein
pMLM3705
|
| p-dCas9-p300-Hygro | p300 (Homo sapiens) | CMV promoter | Hygromycin |
Beck
|
Beck lab Cas9 plasmids
(unpublished)
|
transient expression of dCas9-p300 fusion protein
pMLM3705
|
| p-dCas9-p300-S1396R-S1397R-Hygro | dp300 (Homo sapiens) | CMV promoter | Hygromycin |
Beck
|
Beck lab Cas9 plasmids
(unpublished)
|
transient expression of dCas9-dp300 fusion protein
pMLM3705
|
| JG1202: CAG-human dLbCpf1(D832A)-NLS-3xHA-P65 | dLbCpf1(D832A)-p65 (Other) | CAG | |
Joung
| Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors.
Nat Methods. 2017 Oct 30. doi: 10.1038/nmeth.4483.
|
Mammalian expression vector for catalytically inactive Cpf1 from Lachnospiraceae bacterium (dLbCpf1) fused to p65 activation domain
pCAG-GFP
|
| JG1211: CAG-human dLbCpf1(D832A)-NLS-3xHA-VPR | dLbCpf1(D832A)-VPR (Other) | CAG | |
Joung
| Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors.
Nat Methods. 2017 Oct 30. doi: 10.1038/nmeth.4483.
|
Mammalian expression vector for catalytically inactive Cpf1 from Lachnospiraceae bacterium (dLbCpf1) fused to VPR activator
pCAG-GFP
|
| CAG-LoxpStopLoxp-NLS-dCas9-HA-NLS-NLS-10xGCN4-NLS-P2A-scFv-NLS-P65-HSF1-Flag-T2A-EGFP-WPRE-PolyA | CAG-LSL-dCas9-10xGCN4-P2A-scFv-P65-HSF1-T2A-EGFP-WPRE-PolyA (Other) | | |
Yang
| In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice.
Nat Neurosci. 2018 Jan 15. pii: 10.1038/s41593-017-0060-6. doi: 10.1038/s41593-017-0060-6.
|
Encoding an SPH activation system
PB
|
| dSV40-NLS-dCas9-HA-NLS-NLS-10xGCN4 | dSV40-dCas9-10xGCN4 (Other) | | |
Yang
| In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice.
Nat Neurosci. 2018 Jan 15. pii: 10.1038/s41593-017-0060-6. doi: 10.1038/s41593-017-0060-6.
|
Encoding dCas9-10xGCN4 driven by dSV40 promoter
Lentivirus
|
| dxCas(3.7)-VPR | dxCas(3.7)-VPR (Synthetic) | | |
Liu
| Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
Nature. 2018 Feb 28. pii: nature26155. doi: 10.1038/nature26155.
|
Mammalian expression vector for xCas9 3.7 with VP64-p65-Rta (VPR) fused to its C-terminus
pCMV
Tag
/ Fusion Protein- NLS (N terminal on insert)
|
| dxCas(3.6)-VPR | dxCas(3.6)-VPR (Synthetic) | | |
Liu
| Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
Nature. 2018 Feb 28. pii: nature26155. doi: 10.1038/nature26155.
|
Mammalian expression vector for xCas9 3.6 with VP64-p65-Rta (VPR) fused to its C-terminus
pCMV
Tag
/ Fusion Protein- NLS (N terminal on insert)
|
| pPB-VPR-dSpCas9[StaPL(TI)] | VPR-dSpCas9[StaPL(TI)] (Homo sapiens) | PGK | Puromycin |
Lin
| StaPLs: versatile genetically encoded modules for engineering drug-inducible proteins.
Nat Methods. 2018 Jul;15(7):523-526. doi: 10.1038/s41592-018-0041-z. Epub 2018 Jul 2.
|
Expresses a VPR transcriptional activator fused to the nuclease-deactivated S. pyogenes Cas9, which is governed by an inserted StaPL(TI) module, in mammalian cells. [TI = telaprevir inhibited].
pPB
|
| dCas9-NS3-NLS/VPR | dCas9-NS3-NLS/VPR (Other) | CMV | Hygromycin |
Ngo
| Chemogenetic control of gene expression and cell signaling with antiviral drugs.
Nat Methods. 2018 Jul;15(7):519-522. doi: 10.1038/s41592-018-0042-y. Epub 2018 Jul 2.
|
Encodes the drug-preservable Cas9-NS3-NLS/VPR, which can be used to activate gene expression when combined with an NS3 inhibitor and appropriately designed sgRNA.
pcDNA3
|
| pKLV2-EF1adCas9VP64T2ABsd-W | dCas9VP64-T2A-Blast (Synthetic) | Human EF1a promoter | Blasticidin |
Yusa
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Lentiviral vector expressing Lentiviral vector expressing Lentiviral vector expressing dCas9VP64 under the control of the long human EF1a promoter
pKLV2-EF1a-W
|
| pENTR-EF1adCas9VP64_T2A_MS2p65HSF1-IRESneopA | EF1a promoter, dCas9VP64, MS2p65HSF1, IRESneo (Synthetic) | | Neomycin (select with G418) |
Yusa
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Gateway entry vector carrying human EF1a promoter-driven dCas9VP64-T2A-MS2p65HSF1 with Neomycin resistant marker
pENTR
|
| pENTR-EF1adCas9VP64_T2A_MS2p65HSF1-IRESbsdpA | EF1a promoter, dCas9VP94, MS2p65HSF1, IRESneo (Synthetic) | | Neomycin (select with G418) |
Yusa
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Gateway entry vector carrying human EF1a promoter-driven dCas9VP64-T2A-MS2p65HSF1 with Blasticidine resistant marker
pENTR
|
| pPB-R1R2_EF1adCas9VP64_T2A_MS2p65HSF1-IRESbsdpA | EF1a promoter, dCas9VP94, MS2p65HSF1, IRESneo (Synthetic) | | Blasticidin |
Yusa
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
piggyBac transposon vector carrying human EF1a promoter-driven dCas9VP64-T2A-MS2p65HSF1 with Blasticidin resistant marker
pPB_R1R2-EM7neoPheS
|
| pPB-R1R2_EF1aVP64dCas9VP64_T2A_MS2p65HSF1-IRESbsdpA | VP64-dCas9-VP64-T2A-MS2-p65-HSF1 (Homo sapiens) | | Blasticidin |
Wright
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Expresses VP64-dCas9-VP64 and MS2-p65-HSF1 fusion proteins
pPB-R1R2-EM7NeoPheS
|
| pPB-R1R2_EF1ap300dCas9VP64_T2A_MS2p65HSF1-IRESbsdpA | p300core-dCas9-VP64-T2A-MS2-p65-HSF1 (Homo sapiens) | | Blasticidin |
Wright
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Expresses p300-dCas9-VP64 and MS2-p65-HSF1 fusion proteins
pPB-R1R2-EM7NeoPheS
|
| pJEP303-pAAV-CMV-dSaCas9-VP64-pA | de-catalyzed SaCas9 (Synthetic) | | |
Ploski
| The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons in vivo and Regulated via Doxycycline and Cre-Recombinase.
Front. Mol. Neurosci. (2018) 13
|
A CMV driven de-catalyzed SaCas9 fused to VP64 domain for increased transcription in targeted region
AAV
|
| pJEP304-pAAV-EFS-dSaCas9-VP64-pA | de-catalyzed SaCas9 (Synthetic) | | |
Ploski
| The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons in vivo and Regulated via Doxycycline and Cre-Recombinase.
Front. Mol. Neurosci. (2018) 13
|
A EFS driven de-catalyzed SaCas9 fused to VP64 domain for increased transcription in targeted region
AAV
|
| lenti EF1a-FLAG-dCas9-VPR | dCas9-VPR (Synthetic) | EF1a | |
Day
| A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation.
eNeuro. 2019 Mar 7;6(1). pii: eN-MNT-0495-18. doi: 10.1523/ENEURO.0495-18.2019. eCollection 2019 Jan-Feb.
|
Lentivirus compatible dCas9-VPR construct driven by the EF1a promoter
lentiCRISPR v2
|
| lenti SYN-FLAG-dCas9-VPR | dCas9-VPR (Synthetic) | SYN | |
Day
| A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation.
eNeuro. 2019 Mar 7;6(1). pii: eN-MNT-0495-18. doi: 10.1523/ENEURO.0495-18.2019. eCollection 2019 Jan-Feb.
|
Lentivirus compatible dCas9-VPR construct driven by the human SYN promoter
lentiCRISPR v2
|
| lenti CAG-FLAG-dCas9-VPR | dCas9-VPR (Synthetic) | CAG | |
Day
| A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation.
eNeuro. 2019 Mar 7;6(1). pii: eN-MNT-0495-18. doi: 10.1523/ENEURO.0495-18.2019. eCollection 2019 Jan-Feb.
|
Lentivirus compatible dCas9-VPR construct driven by the CAG promoter
lentiCRISPR v2
|
| pT2K-CAGGS-U6-stuffer-dCAs9-VP160-T2A-IRES-mCherry | dCas9-VP160 | | mCherry |
Roussel
| Mouse medulloblastoma driven by CRISPR activation of cellular Myc.
Sci Rep. 2018 Jun 7;8(1):8733. doi: 10.1038/s41598-018-24956-1.
|
dCas9-VP160 expression in mammalian cells
pT2K-CAGGS-T2TP
|
| pSH231-EF1-BLST-dCas9-VPR | BlastR-P2A-dCas9-VPR (Synthetic) | EF1a | Blasticidin |
Monnat
| New human chromosomal safe harbor sites for genome engineering with CRISPR/Cas9, TAL effector and homing endonucleases
bioRxiv 396390
|
Safe harbor site 231 knock-in vector with BlastR-dCas9-VPR expression cassette
Piggybac
|
| pCMV-sadCas9-VP64 | dCas9-VP64 (Other) | CMV | NONE |
Ahituv
| CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.
Science. 2018 Dec 13. pii: science.aau0629. doi: 10.1126/science.aau0629.
|
An AAV vector expressing S. aureus dCas9 fused to VP64.
pAAV-NLS-dSaCas9-NLS-VPR
|
| pCMV-SpdCas9-VP64 | VP64 (Other) | CMV | NONE |
Ahituv
| CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.
Science. 2018 Dec 13. pii: science.aau0629. doi: 10.1126/science.aau0629.
|
Expresses SpdCas9-Vp64 fusion protein when packaged into AAV
pAAV-Ef1a-FAS-EGFP-WPRE-pA
|
| BICstim-Gag-dCAS9-VPR | GAG (FMLV)-dCAS9-VPR (Homo sapiens) | hCMV | |
Ohlmann
| Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins.
Nat Commun. 2019 Jan 3;10(1):45. doi: 10.1038/s41467-018-07845-z.
|
encodes a GAG-dCAS9-VPR fusion for targeted transcriptional activation.
pcDNA3-like
|
| PB-TetON-dual-SunTag-Hygro | dCas9-GCN4x10_scFv-VP64 (Mus musculus) | Tet-ON | Hygromycin |
Navarro
| The molecular logic of Nanog-induced self-renewal in mouse embryonic stem cells.
Nat Commun. 2019 Mar 7;10(1):1109. doi: 10.1038/s41467-019-09041-z.
|
Endogenous gene activation with the SunTag CRISPR activation system
PiggyBac
|
| FU_tetO_dCas9-VP192-T2A-EGFP | dCas9-VP192-T2A-EGFP (Other) | | EGFP |
Otonkoski
|
Otonkoski plasmids 2018
(unpublished)
|
Lentiviral construct for inducible expression of dCas9-VP192 transcriptional activator and EGFP.
FU_tetOp
|
| IA304: pMAGIC (R4-R3) NLS-Sa dCas9-NLS-VPR | Sa-dCas9/VPR (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS Sa-dCas9 fused to the VPR transcriptional activator for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| KN801: pMAGIC (R4-R3) NLS-x dCas9(3.7)-NLS-VPR | x-dCas9(3.7)/VPR (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS x-dCas9(3.7) fused to the VPR transcriptional activator for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| KL001: pMAGIC (R4-R3) NLS-(SrfI/PmeI)-NLS-VPR | 2x NLS/VPR (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS/VPR scaffold enabling addition of dCas9 mutants into pMAGIC. dCas9 can be inserted via unique SrfI/PmeI restriction sites
pDONR221 P4r-P3r
|
| pHR-pSFFV-dCas9-SunTag-P2A-BFP-dWPRE | dCas9 fused to SunTag(24x) | SFFV | |
Brangwynne
| Liquid Nuclear Condensates Mechanically Sense and Restructure the Genome.
Cell. 2018 Nov 29;175(6):1481-1491.e13. doi: 10.1016/j.cell.2018.10.057.
|
Expresses dCas9-SunTag(24X) fusion and a fluorescent indicator BFP.
pHR
|
| ARB367 | PB_pEF1a-tet3G-P2A-iRFP713_pEF1a-sadCAS9::VPR-P2A-mRuby2-SV40PA_mu6-sgUAS_pUAS-NLS::mAzamiGreen-rgPA (Synthetic) | | |
El-Samad
| A Toolkit for Rapid Modular Construction of Biological Circuits in Mammalian Cells.
ACS Synth Biol. 2019 Nov 15;8(11):2593-2606. doi: 10.1021/acssynbio.9b00322. Epub 2019 Nov 5.
|
Encodes pEF1a driving expression of TET3G P2A iRFP713, pEF1a expressing sadCas9 fused to VPR domain P2A mRuby2, and an sgRNA targeting pUAS expressing mAzamiGreen in a PiggyBac destination vector
MTK0_043
|
| PB_tre_dCas9_VP160 | dCas9 fusion with VP160, Hygromycin resistance | TRE, EF1 alpha | Hygromycin |
Calabrese
| A piggyBac-based toolkit for inducible genome editing in mammalian cells.
RNA. 2019 May 17. pii: rna.068932.118. doi: 10.1261/rna.068932.118.
|
PiggyBac cargo vector expressing doxycycline inducible dCas9-VP160 fusion
piggyBac cargo vector
|
| pAN1646 | p7x_tet-Venus-tADH1-pGal1-dCas9-VP64-Linker-mScarlet-Linker-degronSwitch_A_t12-tPGK1-pZ3-key_A_e18-mTagBFP2-NLS(SV40)-tSSA1 (Synthetic) | | URA3 |
El-Samad
| De novo design of bioactive protein switches.
Nature. 2019 Jul 24. pii: 10.1038/s41586-019-1432-8. doi: 10.1038/s41586-019-1432-8.
|
pTet expression of Venus, Dual inducible expression of dCas9-VP64-mScarlet-degronSwitchA and KeyA-BFP-NLS
Custom MoClo Backbone
|
| VPR_dCas9 | VPR-dCas9-2A-ZsGreen-DR (Synthetic) | CMV | |
Pedersen
| Awakening dormant glycosyltransferases in CHO cells with CRISPRa.
Biotechnol Bioeng. 2020 Feb;117(2):593-598. doi: 10.1002/bit.27199. Epub 2019 Nov 12.
|
Express CHO codon-optimized dCas9 fused to VPR for CRISPR activation. 2A linked ZsGreen1 marker
pJ204
|
| 3XFLAG-VP64-SadCas9-NLS-VP64 | 2xVP64-SadCas9 (Other) | CMV | |
Cohn
| A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene.
Nature. 2019 Aug;572(7767):125-130. doi: 10.1038/s41586-019-1430-x. Epub 2019 Jul 24.
|
3xFLAG VP64 SadCas9 for single guide cloning
pX601
|
| pcDNA3-His:dCas9:nls:10P3 | dCas9 fused to 10 copies of the P3 coiled-coil (Synthetic) | CMV | Neomycin (select with G418) |
Jerala
| A tunable orthogonal coiled-coil interaction toolbox for engineering mammalian cells.
Nat Chem Biol. 2020 Jan 6. pii: 10.1038/s41589-019-0443-y. doi: 10.1038/s41589-019-0443-y.
|
Expresses dCas9 fused to 10 copies of the P3 coiled coil in mammalian cells
pcDNA3
|
| pCC_05 - hU6-BsmBI-sgRNA(E+F)-barcode-EFS-dCas9-NLS-VPR-2A-Puro-WPRE | dSpCas9-VPR (Other) | | Puromycin |
Sanjana
| High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional Modulation.
Cell Rep. 2020 Mar 3;30(9):2859-2868.e5. doi: 10.1016/j.celrep.2020.02.010.
|
Expresses human codon-optimized inactive SpCas9 fused to a transcriptional activator VPR in mammalian cells. For cloning of sgRNAs using BsmBI. Contains a barcode downstream of sgRNA cassette.
lentiCRISPRv2
|
| pCC_06 - hU6-BsmBI-sgRNA(E+F)-barcode-EFS-dCas9NG-NLS-VPR-2A-Puro-WPRE | dSpCas9-NG-VPR (Other) | | Puromycin |
Sanjana
| High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional Modulation.
Cell Rep. 2020 Mar 3;30(9):2859-2868.e5. doi: 10.1016/j.celrep.2020.02.010.
|
Expresses human codon-optimized inactive SpCas9-NG fused to a transcriptional activator VPR in mammalian cells. For cloning of sgRNAs using BsmBI. Contains a barcode downstream of sgRNA cassette.
lentiCRISPRv2
|
| pCC_07 - hU6-BsmBI-sgRNA(E+F)-barcode-EFS-dxCas9-NLS-VPR-2A-Puro-WPRE | dxCas9 3.7-VPR (Other) | | Puromycin |
Sanjana
| High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional Modulation.
Cell Rep. 2020 Mar 3;30(9):2859-2868.e5. doi: 10.1016/j.celrep.2020.02.010.
|
Expresses human codon-optimized inactive xCas9 3.7 fused to a transcriptional activator VPR in mammalian cells. For cloning of sgRNAs using BsmBI. Contains a barcode downstream of sgRNA cassette.
lentiCRISPRv2
|
| pCC_08 - hU6-BsmBI-sgRNA(E+F)-barcode-EFS-dxCas9NG-NLS-VPR-2A-Puro-WPRE | dxCas9-NG-VPR (Other) | | Puromycin |
Sanjana
| High-Throughput Screens of PAM-Flexible Cas9 Variants for Gene Knockout and Transcriptional Modulation.
Cell Rep. 2020 Mar 3;30(9):2859-2868.e5. doi: 10.1016/j.celrep.2020.02.010.
|
Expresses human codon-optimized inactive xCas9-NG fused to a transcriptional activator VPR in mammalian cells. For cloning of sgRNAs using BsmBI. Contains a barcode downstream of sgRNA cassette.
lentiCRISPRv2
|
| pLentiV2-dCas9-VP64 | | | Puromycin |
Ulitsky
|
pLentiV2-dCas9-VP64
(unpublished)
|
Expression of gRNA and dCas9-VP64 from the same plasmid for CRISPRa
entiSAM v2 (Puro) addgene#92062
|
| pCAG-scFvGCN4sfGFP-VP64-GB1 | scFvGCN4sfGFP-VP64-GB1 | CAG | Neomycin (select with G418) |
Hatada
| Synergistic Upregulation of Target Genes by TET1 and VP64 in the dCas9-SunTag Platform.
Int J Mol Sci. 2020 Feb 25;21(5). pii: ijms21051574. doi: 10.3390/ijms21051574.
|
Express scFvGCN4-sfGFP-VP64 fusion protein for dCas9-SunTag mediated targeted gene activation
pCAG
|
| dCas9-VPR_P2A_mCherry | sp-dCas9-VPR_P2A_mCherry (Synthetic) | EF1as | mCherry |
Obenauf
| Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters.
Nat Biotechnol. 2020 Jul 27. pii: 10.1038/s41587-020-0614-0. doi: 10.1038/s41587-020-0614-0.
|
Lentiviral expression plasmid encoding dCas9-VPR and a P2A linked mCherry marker
pRRL
|
| pLV_hUbC-dSpCas9-2xVP64-T2A-BSD | dSpCas9-2xVP64 (Other) | hUbC | Blasticidin |
Gersbach
|
Gersbach lentiviral plasmids
(unpublished)
|
Lentiviral expression of dSpCas9-2xVP64 with blasticidin resistance
FUGW
Tag
/ Fusion Protein- FLAG (N terminal on insert)
|
| lenti SYN-SVI-dCas9-VPR | FLAG-dCas9-VPR containing an SV40 intron (Synthetic) | | |
Day
|
A Cre-dependent CRISPR/dCas9 activation system for gene expression regulation in neurons
(unpublished)
|
Expresses an intron-containing dCas9-VPR fusion driven by human SYN promoter
lentiCRISPR v2
|
| lenti SYN-SVI-DIO-dCas9-VPR | A DIO FLAG-dCas9-VPR cassette containing an SV40 intron (Synthetic) | | |
Day
|
A Cre-dependent CRISPR/dCas9 activation system for gene expression regulation in neurons
(unpublished)
|
Expresses a SYN-driven, intron-containing dCas9-VPR fusion in which the part of the dCas9 cassette is double floxed and in inverted orientation (DIO). Requires Cre-dependent recombination.
lentiCRISPR v2
|